Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001493

Furosemide for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Furosemide, 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid, 5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C12H11ClN2O5S
Numéro CAS:
54-31-9
Poids moléculaire :
330.74
Numéro MDL:
MFCD00010549
Code UNSPSC :
41116107
ID de substance PubChem :
329831456
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

furosemide

Fabricant/nom de marque

EDQM

Pf

220 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl

InChI

1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

Clé InChI

ZZUFCTLCJUWOSV-UHFFFAOYSA-N

Informations sur le gène

human ... SLC12A1(6557)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Furosemide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Inhibits ion co-transport in the kidney.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

F0700000

Furosemide, European Pharmacopoeia (EP) Reference Standard

1287008

Furosemide, United States Pharmacopeia (USP) Reference Standard

F0702000

Furosemide impurity A, European Pharmacopoeia (EP) Reference Standard

1287020

Furosemide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1287030

Furosemide Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR1057

Furosemide, Pharmaceutical Secondary Standard; Certified Reference Material

BP547

Furosemide, British Pharmacopoeia (BP) Reference Standard

PHR1816

Furosemide Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

BP074

4-Chloro-5-sulfamoylanthranilic acid, British Pharmacopoeia (BP) Reference Standard

PHR2457

2,4-Dichlorobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Danger

Mentions de danger

H302,H360FD

Classification des risques

Acute Tox. 4 Oral - Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Phillip J Newton et al.
Journal of pain and symptom management, 36(4), 424-441 (2008-05-13)
Dyspnea is a common and distressing symptom associated with multiple chronic illnesses and high levels of burden for individuals, their families and health care systems. The subjective nature dyspnea and a poor understanding of pathophysiological mechanisms challenge the clinician in
Kurt A Wargo et al.
The Annals of pharmacotherapy, 43(11), 1836-1847 (2009-10-22)
To review the literature regarding the pharmacokinetic profiles, comparative safety and efficacy, and comparative costs of loop diuretics to evaluate the current clinical usefulness of furosemide. A search of MEDLINE (1966-June 2009) was conducted using the terms furosemide, torsemide, bumetanide
Adam D DeVore et al.
European journal of heart failure, 17(3), 340-346 (2015-01-27)
Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these factors. We analysed data
Christianne L Roumie et al.
Stroke, 46(2), 465-470 (2015-01-01)
We examined blood pressure 1 year after stroke discharge and its association with treatment intensification. We examined the systolic blood pressure (SBP) stratified by discharge SBP (≤140, 141-160, or >160 mm Hg) among a national cohort of Veterans discharged after
Susan B LeGrand et al.
Annals of internal medicine, 149(4), 259-263 (2008-08-20)
Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique